Jpmorgan Chase & CO Igm Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 6,787 shares of IGMS stock, worth $60,336. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,787
Previous 7,073
4.04%
Holding current value
$60,336
Previous $48,000
133.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding IGMS
# of Institutions
81Shares Held
20.7MCall Options Held
68KPut Options Held
52.2K-
Baker Bros. Advisors LP New York, NY4.09MShares$36.4 Million0.72% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.01MShares$35.7 Million0.01% of portfolio
-
Siren, L.L.C. New York, NY3.33MShares$29.6 Million2.75% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$27.3 Million3.32% of portfolio
-
Goldman Sachs Group Inc New York, NY1.26MShares$11.2 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $258M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...